Dual-biomarker targeting agent helps diagnose, treat prostate cancer

A dual diagnostic and therapeutic compound binds GRPr and PSMA with high specificity and sensitivity. By simultaneously binding both of these prostate cancer biomarkers this compound can provide highly accurate results via PET or SPECT imaging, without the discomfort and costs associated with additional tests and exams.